LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials.

    Balevic, Stephen J / Hornik, Christoph P / Green, Thomas P / Clowse, Megan E B / Gonzalez, Daniel / Maharaj, Anil R / Schanberg, Laura E / Eudy, Amanda M / Swamy, Geeta K / Hughes, Brenna L / Cohen-Wolkowiez, Michael

    The Journal of rheumatology

    2020  

    Abstract: Objective: To characterize hydroxychloroquine (HCQ) exposure in patients with rheumatic disease ... the coronavirus disease 2019 caused by SARS-CoV-2 (COVID-19).: Methods: We evaluated total HCQ concentrations ... for rheumatic diseases, including children and non-pregnant/pregnant adults, are unlikely to achieve total serum or ...

    Abstract Objective: To characterize hydroxychloroquine (HCQ) exposure in patients with rheumatic disease receiving longterm HCQ compared to target concentrations with reported antiviral activity against the coronavirus disease 2019 caused by SARS-CoV-2 (COVID-19).
    Methods: We evaluated total HCQ concentrations in serum and plasma from published literature values, frozen serum samples from a pediatric systemic lupus erythematosus trial, and simulated concentrations using a published pharmacokinetic model during pregnancy. For each source, we compared observed or predicted HCQ concentrations to target concentrations with reported antiviral activity against SARS-CoV-2.
    Results: The average total serum/plasma HCQ concentrations were below the lowest SARS-CoV-2 target of 0.48 mg/l in all studies. Assuming the highest antiviral target exposure (total plasma concentration of 4.1 mg/l), all studies had about one-tenth the necessary concentration for
    Conclusion: We found that the average patient receiving treatment with HCQ for rheumatic diseases, including children and non-pregnant/pregnant adults, are unlikely to achieve total serum or plasma concentrations shown to inhibit SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-05-11
    Publishing country Canada
    Document type Journal Article
    ZDB-ID 194928-7
    ISSN 1499-2752 ; 0315-162X
    ISSN (online) 1499-2752
    ISSN 0315-162X
    DOI 10.3899/jrheum.200493
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials

    Balevic, Stephen J / Hornik, Christoph P / Green, Thomas P / Clowse, Megan E B / Gonzalez, Daniel / Maharaj, Anil R / Schanberg, Laura E / Eudy, Amanda M / Swamy, Geeta K / Hughes, Brenna L / Cohen-Wolkowiez, Michael

    J. rheumatol

    Abstract: ... with rheumatic disease are urgently needed to characterize the efficacy, safety, and target exposures for HCQ. ... OBJECTIVE: To characterize hydroxychloroquine (HCQ) exposure in patients with rheumatic disease ... for HCQ in the setting of SARS-CoV-2 is unknown, well-designed clinical trials that include patients ...

    Abstract OBJECTIVE: To characterize hydroxychloroquine (HCQ) exposure in patients with rheumatic disease receiving longterm HCQ compared to target concentrations with reported antiviral activity against the coronavirus disease 2019 caused by SARS-CoV-2 (COVID-19). METHODS: We evaluated total HCQ concentrations in serum and plasma from published literature values, frozen serum samples from a pediatric systemic lupus erythematosus trial, and simulated concentrations using a published pharmacokinetic model during pregnancy. For each source, we compared observed or predicted HCQ concentrations to target concentrations with reported antiviral activity against SARS-CoV-2. RESULTS: The average total serum/plasma HCQ concentrations were below the lowest SARS-CoV-2 target of 0.48 mg/l in all studies. Assuming the highest antiviral target exposure (total plasma concentration of 4.1 mg/l), all studies had about one-tenth the necessary concentration for in vitro viral inhibition. Pharmacokinetic model simulations confirmed that pregnant adults receiving common dosing for rheumatic diseases did not achieve target exposures; however, the models predict that a dosage of 600 mg once a day during pregnancy would obtain the lowest median target exposure for most patients after the first dose. CONCLUSION: We found that the average patient receiving treatment with HCQ for rheumatic diseases, including children and non-pregnant/pregnant adults, are unlikely to achieve total serum or plasma concentrations shown to inhibit SARS-CoV-2 in vitro. Nevertheless, patients receiving HCQ long term may have tissue concentrations far exceeding that of serum/plasma. Because the therapeutic window for HCQ in the setting of SARS-CoV-2 is unknown, well-designed clinical trials that include patients with rheumatic disease are urgently needed to characterize the efficacy, safety, and target exposures for HCQ.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #32393664
    Database COVID19

    Kategorien

  3. Article: Evidence of protective effect of hydroxychloroquine to prevent COVID-19

    Joob, Beuy / Wiwanitkit, Viroj

    J. rheumatol

    Abstract: ... with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials [1]."Balevic ... needed to characterize the efficacy, safety, and target exposures for hydroxychloroquine [1]." ... noted that "well-designed clinical trials that include patients with rheumatic disease are urgently ...

    Abstract We would like to share ideas on the report on "Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials [1]."Balevic noted that "well-designed clinical trials that include patients with rheumatic disease are urgently needed to characterize the efficacy, safety, and target exposures for hydroxychloroquine [1]."
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #32451353
    Database COVID19

    Kategorien

  4. Article: Evidence of Protective Effect of Hydroxychloroquine on COVID-19

    Joob, Beuy / Wiwanitkit, Viroj

    J. rheumatol

    Abstract: ... Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials"1 Balevic noted ... that "well-designed clinical trials that include patients with rheumatic disease are urgently needed ... We would like to share ideas on the report "Hydroxychloroquine in Patients with Rheumatic Disease ...

    Abstract We would like to share ideas on the report "Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials"1 Balevic noted that "well-designed clinical trials that include patients with rheumatic disease are urgently needed to characterize the efficacy, safety, and target exposures for hydroxychloroquine1".
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #32451353
    Database COVID19

    Kategorien

To top